Atypical femur fractures, a rare adverse event of bisphosphonates in oncology: Case reportspañol

Abstract

Bisphosphonates are one of the fundamental pillars in the management of bone morbidity in patients with diferent types solid tumors. However, despite the experience that we have had for its use for decades, there are adverse events such as atypical fractures (AF) that due to their low frequency can go unnoticed and not receive adequate management. There are few reports in the literature about AF in cancer treatments. We present a case in which a patient with a metachronous breast tumor with bone metastases at initial diagnosis, currently in remission, presents an AF of the femur after receiving bisphosphonates for 8 years.